Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911453 · ClinicalTrials.gov registry record · Early Phase 1
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
A Early Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03911453 is a Early Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 20 participants.
The verdict
NCT03911453, a Early Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single arm window of opportunity trial conducted in patients with early stage triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase (PARP) inhibitor will increase expression of programmed cell death-1 with ligand (PD-L1) in triple negative breast tumors.
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-19 |
| Est. Completion | 2021-07-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911453
The ClinicalTrials.gov registry entry for NCT03911453 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT03911453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03911453 about?
NCT03911453 is a clinical study titled "Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors". This is a single arm window of opportunity trial conducted in patients with early stage triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase (PARP) inhibitor will increase expression of programmed cell death-1 with ligand (PD-L1) in triple negative breast tumors.
What is the current status of trial NCT03911453?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-04-19. Estimated completion is 2021-07-16.
What interventions are being tested in trial NCT03911453?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03911453?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.